Outlook Therapeutics, Inc. (OTLK) is a Healthcare stock trading at $0.65 (as of 2026-08-21), with a market capitalization of $78.25M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Understand Outlook Therapeutics, Inc.: how it makes money
Outlook Therapeutics is a pharmaceutical-products company, and the provided information does not detail its specific product revenue streams, but its latest results show gross margin 71% and operating margin -1046%.
Gross margin 71% has not translated into operating profit, with operating margin -1046% indicating heavy operating costs relative to gross profit.
Business quality (Unprofitable): Unprofitable, with operating margin -1046%.
Bull case
Gross margin hints at unit strength: The company reports gross margin 71%, which can suggest favorable gross profit economics if product revenue scales. That is an important prerequisite for any path to operating profitability.
Bear case
Operating losses dominate profitability: Operating margin -1046% shows operating expenses overwhelm gross profit, so the business is not converting its gross margin into operating earnings. This creates a fragile profit model until cost structure and results improve.
Valuation — source: SEC EDGAR (first-party)
Price
$0.65
Market Cap
$78.25M
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)
$1.41M
Net Margin
-4416.2%
Revenue Growth (YoY)
56.0%
EPS Growth (YoY)
-55.9%
Financial Health — source: SEC EDGAR
Altman Z-Score
-58.81 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)
21.7
Industry P/E (Pharmaceutical Products)
17.2
Company
Sector
Healthcare
Industry
Pharmaceutical Products
Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)